Expand IMNM Menu
IMNM MENU

IMNM Latest Press Releases

-- September 8, 2026 --

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:02 PM

-- September 2, 2026 --

Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference Business Wire 7:45 AM

-- August 11, 2026 --

Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update Business Wire 4:02 PM

-- August 6, 2026 --

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:02 PM

-- July 20, 2026 --

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors Business Wire 7:30 AM

-- July 8, 2026 --

Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors Business Wire 7:30 AM

-- July 7, 2026 --

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:02 PM

-- June 11, 2026 --

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors Business Wire 7:30 AM

-- June 4, 2026 --

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:02 PM

-- May 30, 2026 --

Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting Business Wire 8:00 AM

-- May 27, 2026 --

Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference Business Wire 8:00 AM

-- May 12, 2026 --

Immunome Reports First Quarter 2026 Financial Results and Provides Business Update Business Wire 4:02 PM

-- May 5, 2026 --

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:00 PM

-- April 29, 2026 --

Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors Business Wire 7:30 AM

-- April 21, 2026 --

Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting Business Wire 10:30 AM
Market Data Delayed 15 Minutes